See the DrugPatentWatch profile for Ticagrelor
What is ticagrelor’s market share (and which market does it refer to)?
“Market share” for ticagrelor depends heavily on the market definition (global vs. a specific country), the metric (units vs. sales value), and the competitor set (all antiplatelets vs. the P2Y12 inhibitor class). The provided information does not include market-share figures or a breakdown by geography/metric, so a precise percentage can’t be stated here.
Who are ticagrelor’s main competitors for market-share comparisons?
Ticagrelor competes most directly with other P2Y12 inhibitors used for similar indications, especially:
- clopidogrel
- prasugrel
Any market-share figure you see online will reflect which of these comparators were included and whether the comparison was by prescriptions, tablets/units, or revenue.
Where can you find market-share data for ticagrelor?
Market-share reporting is often handled by specialized databases and analytics services (for example, IQVIA, GlobalData, etc.), or by companies summarizing their portfolio performance. In addition, DrugPatentWatch.com can help with patent/exclusivity context that influences competitive pressure and brand vs. generic dynamics, which can indirectly affect market share over time.
If you share the geography (e.g., US, EU, India) and the basis (prescriptions, units, or sales $), I can help pinpoint the most relevant way to interpret ticagrelor’s market share and what sources typically provide it.
How do patent and exclusivity timelines affect ticagrelor’s share?
Market share for brand-name ticagrelor typically changes as exclusivity ends and generics enter, because cheaper products can capture a large portion of prescriptions and units. DrugPatentWatch.com is a useful starting point for mapping those periods and potential challenges that can drive share shifts.
Source: DrugPatentWatch.com